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Impairment of myocardial fatty acid substrate metabolism is
characteristic of late-stage heart failure and has limited treat-
ment options. Here, we investigated whether inhibition of
G-protein-coupled receptor kinase 2 (GRK2) could counteract
the disturbed substrate metabolism of late-stage heart failure.
The heart failure-like substratemetabolismwas reproduced in a
novel transgenic model of myocardium-specific expression of
fatty acid synthase (FASN), the major palmitate-synthesizing
enzyme. The increased fatty acid utilization of FASN transgenic
neonatal cardiomyocytes rapidly switched to a heart failure phe-
notype in an adult-like lipogenic milieu. Similarly, adult FASN
transgenic mice developed signs of heart failure. The develop-
ment of disturbed substrate utilization of FASN transgenic car-
diomyocytes and signs of heart failure were retarded by the
transgenic expression of GRKInh, a peptide inhibitor of GRK2.
Cardioprotective GRK2 inhibition required an intact ERK axis,
which blunted the induction of cardiotoxic transcripts, in part
by enhanced serine 273 phosphorylation of Pparg (peroxisome
proliferator-activated receptor ). Conversely, the dual-specific
GRK2 and ERK cascade inhibitor, RKIP (Raf kinase inhibitor
protein), triggered dysfunctional cardiomyocyte energetics and
the expression of heart failure-promoting Pparg-regulated
genes. Thus, GRK2 inhibition is a novel approach that targets
the dysfunctional substrate metabolism of the failing heart.
Heart failure is a debilitating syndrome that involves insuffi-
cient cardiac performance. Multiple pathomechanisms have
been elucidated, but treatment options remain insufficient, and
hence the mortality of heart failure is high (1). The causes of
heart failure are complex with ischemic heart disease being the
most frequently associated condition (2). Co-existing disorders
such as diabetes, hypertension, and obesity further deteriorate
symptoms (3). Despite having a different etiology, late-stage
heart failure is commonly characterized by severe changes in
myocardial substrate metabolism, with a switch from fatty acid
oxidation toward predominant glycolysis (4–6). Conflicting
evidence exists as to whether this substrate switch is beneficial
or detrimental (7), but several previous studies have indicated
that an increased availability of lipid substrates that counteract
the substrate switch could improve cardiac function (7, 8).
Moreover, treatment options, which improve substrate avail-
ability, are attractive because the failing heart is often consid-
ered to be “an engine running out of fuel” (9).
Following this concept, we aimed to investigate the impact of
improved cardiac substrate availability by generating trans-
genic mice with myocardium-specific expression of fatty acid
synthase (FASN), the major palmitate-synthesizing enzyme.
Such an approach is also supported by data obtained for myo-
cardium-specific Fasn deficiency, which have revealed the car-
dioprotective potential of Fasn (10). Moreover, hearts from
patients with heart failure showed an increased expression and
protein level of FASN2 (10, 11). By generation of transgenic
mice, we found that FASN transgenic mice developed a heart
failure-like phenotype with impaired cardiomyocyte substrate
use. In search for a treatment approach for the disturbed car-
diac substrate metabolism, we focused on the role of GRK2
inhibition because GRK2 inhibition could counteract cardioli-
potoxicity by promotion of a cardiomyocyte survival program
(12, 13) and resensitization of the cardioprotective adiponectin
receptor 1 (14–16). For GRK2 inhibition in vivo, we used
GRKInh, a small peptide inhibitor derived from the first intra-
cellular loop of the 2-adrenergic receptor (12, 17). Our data
with GRKInh show that GRK2 inhibition counteracts the heart
failure-related cardiacmetabolic dysfunction and signs of heart
failure of FASN transgenic mice.
Experimental Procedures
Generation of Transgenic Mice and Animal Experiments—
Transgenic mice were generated as described (12) with minor
modifications. Briefly, for the generation of transgenic mice
withmyocardium-specific expression of FASN, we constructed
a transgene that placed the FASN cDNA under the control of
the -myosin heavy chain (-MHC) promoter (12). For the
generation of transgenic mice with myocardium-specific
expression of UCP1 (uncoupling protein-1), PPARG, and
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PPARG-S273A (isoform-1, which lacks amino acids 1–28 of
isoform-2; serine 273 refers to the numbering of isoform-2), a
similar approachwas used. The plasmid sequencewas removed
by NotI digestion, and the purified linear DNA (2 ng/l) was
injected into fertilized oocytes of superovulated B6 (C57BL/6J)
mice. For generation of transgenic Tg-PPARG and Tg-PPARG-
S273A mice, fertilized oocytes from non-transgenic and
Tg-GRKInh mice (transgenic mice with myocardium-specific
expression of GRKInh, a GRK2-specific peptide inhibitor with
the peptide sequence MAKFERLQTVTNYFITSE) were used.
Transgenic mice with myocardium-specific expression of
GRKInh or human RKIP (PEBP1) were generated and charac-
terized previously (12).Mouse lines in the studywere deposited
into the JAX repository (The Jackson Laboratory) and have
the following strain ID numbers: 911818 (C57BL/6Tg
(MHCPEBP1)1 Sjaa); 911822 (C57BL/6Tg(MHCGRK-Inh)1
Sjaa); 911826 (C57BL/6Tg(MHCFASN)1 Sjaa); and 911830
(C57BL/6Tg(MHCUCP1)1 Sjaa).
The effect of rosiglitazone-induced Pparg activation was
analyzed with 8-month-old male ApoE/ mice, which had
received 30 mg/kg/day rosiglitazone for 2 months. Untreated,
age-matched ApoE/, and non-transgenic B6 mice served as
control groups. Abdominal aortic constriction (AAC) was per-
formed in 4-month-old male B6 mice to trigger pressure over-
load-induced cardiac hypertrophy and signs of heart failure
(11). Age-matched control mice underwent the identical surgi-
cal procedure except for ligation of the aorta (sham-operated
mice). All of the mice were kept on a 12-h light/12-h dark
regime and had free access to food and water. The ApoE/
mice were fed a rodent chow that contained 7% fat and 0.15%
cholesterol (AIN-93-based diet), whereas B6 mice were fed a
standard rodent chow containing 4.5% fat.
Transthoracic echocardiographywas performedwith aVivid
7 echocardiograph (GE Healthcare) with a 12MHz linear array
transducer similarly as described previously (11). The left ven-
tricular ejection fraction was calculated in the M-mode of the
parasternal long axis view using the formula of Teichholz.
Recordings were interpreted off line using EchoPac Pc 3.0 soft-
ware (GE Healthcare).
Animal experiments were performed in accordance with
National Institutes of Health guidelines, and they were
reviewed and approved by the local committee on animal care
and use (University of Zurich).
Whole Genome Microarray Gene Expression Analysis—
Whole genome microarray gene expression analysis of cardiac
tissue was performed using Affymetrix GeneChip Mouse
genome MG430 2.0 arrays essentially as described previously
(18). Gene ontology analyses of microarray data were per-
formedwith GCOS and/or RMA-processed data using Gene-
Spring GX software (Agilent). Probe sets, which were signif-
icantly up-regulated in failing hearts (fold change2 relative
to the respective control group and p  0.01) were used for
gene ontology classification. Microarray gene expression
data are available at the NCBI GEO database accession num-
bers GSE25765-8 (GSE25765, GSE25766, GSE25767, and
GSE25768), GSE28031, and GSE49351.
Gene expression of selected genes was also analyzed by real
time quantitative (q) RT-PCR with a LightCycler 480 (Roche
Diagnostics). Sequences of the forward and reverse primers
were as follows: Acaca forward 5-GCCTCCGTCAGCTCAG-
ATAC-3 and Acaca reverse 5-GACCACCGACGGATAGA-
TCG-3; Adipoq forward 5-ACTGCAACATTCCGGGACTC-
3 and Adipoq reverse 5-GAGGCCTGGTCCACATTCTT-3;
Fasn forward 5-GGCCCCTCTGTTAATTGGCT-3 and Fasn
reverse 5-CGCTTGTTGGTGGACACTTG-3; FASN for-
ward 5-TCGTGTTGACTTCTCGCTCC-3 and FASN re-
verse 5-AAGCCGTAGTTGCTCTGTCC-3; PPARG forward
5-GCTCCGTGGATCTCTCCGTA-3 and PPARG reverse
5-AGCTTTATCTCCACAGACACGA-3; Retn forward 5-
GTCCTGCTAAGTCCTCTGCCAC-3 and Retn reverse 5-
GGCTGCTGTCCAGTCTATCCTTG-3; and Ucp1 forward
5-CACTGCCAAAGTCCGCCTTCAGA-3 andUcp1 reverse
5-GCAGGCAGACCGCTGTACAGTT-3.
Lentivirus-mediated Down-regulation of Fasn and Ucp1 by
RNAi in Vivo—For the down-regulation of Fasn expression in
vivo, ApoE/micewere transduced by intraperitoneal admin-
istration of a replication-incompetent lentivirus (1  108 cop-
ies/mouse in PBS), which down-regulates Fasn by polymerase
II-dependent expression of a pre-miRNA targeting the Fasn
RNA by RNAi. Endogenously expressed Ucp1 was down-regu-
lated by the transduction of B6 mice with a lentivirus that
expressed a pre-miRNA targetingUcp1 by RNAi. The lentiviral
expression plasmids were generated by inserting the indicated
double-stranded oligonucleotides that encoded an engineered
pre-miRNA sequence into the pLenti6/V5-Dest Gateway
Vector (Invitrogen): miFasn top strand 5-TGCTGATAACT-
TGGAGTTCGGGTCTTGTTTTGGCCACTGACTGACAA-
GACCCGCTCCAAGTTAT-3 and miFasn bottom strand
5-CCTGATAACTTGGAGCGGGTCTTGTCAGTCAGTG-
GCCAAAACAAGACCCGAACTCCAAGTTATC-3; miUcp1
top strand 5-TGCTGTTTGATCCCATGCAGATGGCT-
GTTTTGGCCACTGACTGACAGCCATCTATGGGATC-
AAA-3 and miUcp1 bottom strand 5-CCTGTTTGATCC-
CATAGATGGCTGTCAGTCAGTGGCCAAAACAGCCAT-
CTGCATGGGATCAAAC-3. A pseudotyped lentivirus was
produced by co-transfection of 293FT cells with the lentiviral
plasmid and a mixture of packaging plasmids pLP1, pLP2,
and pLP/VSVG (Invitrogen). To quantify the lentivirus inte-
gration in vivo, we used primers that comprised sequences
that were derived from the cytomegalovirus immediate early
promoter and the pre-miRNA sequence. Down-regulation of
Fasn (or Ucp1) expression was confirmed by real time quan-
titative RT-PCR after the transduction of mice or isolated
neonatal mouse cardiomyocytes with miFasn-lentivirus (or
miUcp1-lentivirus).
Antibodies—The following antibodies were used for immu-
nohistochemistry, immunofluorescence, and immunoblotting:
anti-ARRB1 (-arrestin-1) antibodies, raised in mouse against
recombinantARRB1 (12); anti-Agtr1 (AT1R) antibodies, which
were raised in rat against the carboxyl-terminal region of Agtr1
(19); anti-FASN antibodies, which were raised in rabbit against
an antigen encompassing amino acids 2205–2504 of FASN (11);
anti-GRK2 (ADRBK1) antibodies, raised in rabbit against
recombinant GRK2 protein (12); anti-GRK5 antibodies, raised
in rabbit against recombinant GRK5 protein (12); anti-GRKInh
antibodies, raised in rabbit against GRKInh (12); anti-Pparg
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antibodies, raised in rabbit against an antigen encompassing
amino acids 8–106 of PPARG (Santa Cruz Biotechnology Inc.)
or synthetic phosphopeptides derived from PPARG around the
phosphorylation site of Ser-273 or Ser-112 (BIOSS antibodies;
Abcam); and Ucp1/UCP1 antibodies raised in rabbit against an
antigen encompassing amino acids 288–302 of mouse/human
Ucp1/UCP1 (11). For the immunohistological and immunoblot
detection of activated phospho-ERK1/2, phospho-ERK1/2-
specific antibodies were used detecting activated ERK1/2 phos-
phorylated at Thr-202Tyr-204 of ERK1 and Thr-185Tyr-
187 of ERK2 (E10mousemAb, Cell Signaling). For immunoblot
detection of ERK1/2, the ERK1/2-specific antibodies raised in
rabbits (Cell Signaling) were used, and immunofluorescence
detection of p38MAPKon cardiac sectionswas performedwith
anti-p38 antibodies (Cell Signaling). The immunoblot detec-
tion of activated AMPK (Prkaa1/2; protein kinase, AMP-acti-
vated 1/2 catalytic subunit) phosphorylated on Thr-183/172
was detectedwith antibodies raised in rabbit against a synthetic
peptide corresponding to residues that surrounded Thr-172
(40H9, Cell Signaling). Immunoblotting and immunohisto-
chemistry were routinely used to determine and confirm the
cross-reactivity of the antibodieswith the respectivemouse and
human proteins.
Immunohistology Analyses and Immunofluorescence—For
immunohistology, we used paraffin sections or cryosections of
mouse heart specimens. Immunohistological detection of Fasn
(FASN) was performed with affinity-purified polyclonal anti-
bodies as described (11). Methods describing Oil Red O stain-
ing, immunofluorescence detection of proteins, and immuno-
histology for activated phospho-ERK1/2 in paraffin sections or
cryosections have been described previously (11, 12). Immuno-
histology sections were imaged with a Leica DMI6000 micro-
scope equipped with a DFC420 camera, and immunofluores-
cence imaging was performedwith a Leica (TCS) confocal laser
microscope.
Immunoblot Detection of Proteins—For immunoblot detec-
tion of proteins, cardiac tissue was pulverized in liquid nitrogen
and extracted with RIPA buffer supplemented with protease/
phosphatase inhibitor mixture, as described previously (20).
Detection of proteins was performed with affinity-purified
antibodies or F(ab)2 fragments of the respective antibodies (11,
12) after separation of proteins by SDS-PAGE and subsequent
electrophoretic protein transfer to PVDF membranes. Bound
antibody was visualized with F(ab)2 fragments of enzyme-cou-
pled secondary antibodies (Dianova) or by enzyme-coupled
protein A (Merck Millipore) as applicable and was followed by
enhanced chemiluminescent detection (ECL Prime, Amer-
sham Biosciences).
Functional Assays—Mouse or rat neonatal cardiomyocytes
were isolated and transfected as described (12, 21). Fibro-
blasts were removed by preplating for 1 h at 37 °C. Cardiomyo-
cytes were collected and cultivated in minimum essential
medium supplemented with 5% FCS and 25 mg/liter BrdU
(5-bromo-2-deoxyuridine). For knockdown of Fasn andUcp1,
neonatal cardiomyocytes were transfected with stealth RNAi
targeting the coding sequence of rat ormouseFasn (nucleotides
428–452 and 1990–2014; Invitrogen) and Ucp1 (nucleotides
289–313 and 401–425; Invitrogen). For cardiomyocyte expres-
sion of PPARG and PPARG-S273A, the human cDNAs encod-
ing PPARG and PPARG-S273A were inserted into the KpnI/
XbaI sites of pcDNA3 (Invitrogen). All of the mutants and
constructs that were generated by PCR were sequenced
entirely. DNA strand breaks were determined in situ by the
terminal deoxynucleotidyltransferase-mediated dUTP nick
end labeling (TUNEL) technique (Roche Applied Science) (12).
Measurement of the [ATP] of cardiac tissue extracts was per-
formed as described (11), and Pparg transcription factor DNA
binding activity was determined with a Pparg transcription fac-
tor assay kit (Abcam). Cellular cAMP, total cardiac free fatty
acids (FFA), and triacylglycerol (TAG) contents were analyzed
as detailed previously (11, 21). Cardiac contents of diacylglyc-
erol (DAG) and ceramides were determined with the DAG
kinase assay method as described (22).
Measurement of Cardiomyocyte Substrate Metabolism—We
used a Seahorse XF24 extracellular flux analyzer (Seahorse Bio-
science) to determine the cardiomyocyte substratemetabolism.
The oxygen consumption rates (OCR) (pmol/min) and extra-
cellular acidification rates (ECAR) (the H production rate,
mpH/min), of neonatal cardiomyocytes (10 000 cells/well)
plated onCell-Tak-coated plates (Discovery Labware Inc., Bed-
ford, MA) were measured in assay medium (i.e. unbuffered
DMEM supplemented with 5.5 mM glucose and 0.5 mM carni-
tine) according to the Installation and Operation Manual from
Seahorse Bioscience. The oxidation of endogenous fatty acids
(without exogenously added palmitate, to detect the function of
transgenic FASN expression) was determined by measurement
of the absolute and relative OCR that was inhibited by the
CPT-1 (carnitine palmitoyl transferase 1) inhibitor, Etomoxir
(50 M). The extent of glycolysis was determined by measure-
ment of the absolute and relative ECAR, whichwas inhibited by
50 mM 2-deoxyglucose. As indicated, we also determined the
effect of an adult-like lipogenic milieu by the cultivation of car-
diomyocytes for 10 days with a 3F protocol that consisted of
insulin (5 g/ml), 3-isobutylmethylxanthine (0.25 mM), and
dexamethasone (0.5 M) (23), which were added as supple-
ments to the standardmedium.As a control for the 3F protocol,
we used cardiomyocytes that were cultivated for 10 days under
standard conditions. Long term cultivation of neonatal car-
diomyocytes is a model of in vitro senescence characterized by
metabolic deficiencies (24), which could account for the overall
low -oxidation rate of 5–25% in our experiments. Metabolic
flux experiments were performed on 6 wells of a 24-well plate
(technical replicates) and were reproduced at least three times
(biological replicates). Theoligomycin-insensitiveOCR (amea-
sure of mitochondrial uncoupling) was determined after the
addition of 2.5 M oligomycin. The non-mitochondrial OCR
that remained after the addition of rotenone/antimycin A (2
M) was subtracted.
Statistical Analyses—The results are presented as the
means  S.D. unless otherwise specified. The p values were
calculated with Student’s t test. Analysis of variance was per-
formed for comparisons between more than two groups fol-
lowed by a post test (Tukey’s multiple comparison test unless
otherwise specified), and statistical significance was set at a p
value of0.05 unless otherwise stated.
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Results
FASNTransgenic CardiomyocytesDeveloped aDysfunctional
Cardiac Substrate Metabolism—A dysfunctional cardiac sub-
strate metabolism is a common feature of late-stage heart fail-
ure with limited treatment options. To reproduce the energy
substrate use of heart failure patients and experimentalmodels,
which commonly show up-regulation of the major palmitate-
synthesizing enzyme, FASN (10, 11), we generated a transgenic
model with myocardium-specific FASN expression under the
control of the -MHC promoter (Fig. 1, A and B). Immunoblot
detection of the FASN protein confirmed transgenic protein
expression in hearts frommice with stable genomic integration
of the FASN transgene, whereas the Fasn protein was barely
detectable in non-transgenic B6 hearts (Fig. 1C). Two different
transgenic lines (derived from founders numbers 3 and 9) were
established, which showed comparable FASN protein levels
(Fig. 1C). All of the experiments were independently performed
with these two transgenic lines.
After the generation of the transgenic mouse lines, the met-
abolic energetics of isolated neonatal FASN transgenic (Tg-
FASN) cardiomyocytes was determinedwith a Seahorse Biosci-
ence XF24 Extracellular Flux Analyzer. We measured the
-oxidation of endogenous fatty acids by the Etomoxir-sensi-
tive fraction of the OCR, and glycolysis by the 2-deoxyglucose-
sensitive ECAR (Fig. 1, D and E). Compared with non-trans-
genic controls, FASN transgenic cardiomyocytes showed
significantly more -oxidation under basal conditions (22.7 
1.5% versus 5.3 0.9%; Fig. 1, F and G). This finding indicated
that FASN increases the substrate availability of cardiomyo-
cytes for -oxidation.
FIGURE 1. FASN transgenic cardiomyocytes developed a dysfunctional cardiac substratemetabolism. A, scheme of the-MHC-FASN vector used for the
generation of FASN transgenicmice. B, identification of the-MHC-FASN transgene in the genomicDNAof different foundermice by PCR. The asterisksdenote
the amount of the FASN transgene-specific PCR product (***, **, *,,	, amount of PCR product obtainedwith 2 ng of plasmid template (P)). C, immunoblot
(IB) detectionof theFASNprotein inhearts fromdifferent foundermicewith FASN-specific antibodies (IB: FASN). Theasterisks indicate theamountof transgenic
FASN protein relative to the non-transgenic control after normalization to Gnb (***, 2.5-fold; **, 2.3-fold; *, 1.8-fold (lane 5) and 1.4-fold (lane 10) increase over
control). The lower panel shows a control immunoblot detecting Gnb. D and E, real time measurement of the OCR and ECAR of neonatal cardiomyocytes
isolated from FASN transgenic (Tg-FASN) and B6 control mice under basal conditions (left panel) and after the creation of an adult-like lipogenic milieu by the
3F protocol for 10 days (right panel). The addition of the CPT-1 inhibitor Etomoxir (Etom., 50M) and 2-deoxyglucose (2-DG, 50 mM) is indicated by the arrows.
The relative values normalized to the baseline (i.e. the secondmeasurement point set to 100%) (D) and the absolute values of OCR and ECAR (E) are presented.
FandG, etomoxir-blocked fractionof theOCR represents fatty acid-oxidation; the2-deoxyglucose-blocked fractionof theECAR representsglycolysis, and the
ratio of glycolysis/-oxidation was calculated. The data are shown as the means S.D.; n	 6 technical replicates (D and E), and n	 3 biological replicates (F
and G); ***, p	 0.0002 (F, left panel) and 0.0004 (G, right panel); **, p	 0.0032 (F,middle panel), 0.0079 (F, right panel) and 0.0071 (G, left panel); p	 0.7324 (G,
middle panel).
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We next determined the effect of an adult-like lipogenic
milieu on neonatal cardiomyocytes by treatment with a 3F pro-
tocol consisting of insulin, 3-isobutylmethylxanthine, and dex-
amethasone for 10 days (23). In control cardiomyocytes, the 3F
protocol switched the embryo-like metabolism dominated by
glycolysis (25) to an adult-like metabolism, which was charac-
terized by an increased baseline OCR (Fig. 1E), and more fatty
acid -oxidation (Fig. 1G). In contrast, FASN transgenic car-
diomyocytes developed a heart failure-like phenotype with an
overall depressed substrate metabolism (Fig. 1E), and predom-
inant glycolysis (Fig. 1F). Thus, the increased availability of the
lipid substrate, palmitate, did not protect neonatal cardiomyo-
cytes from a substrate switch to a heart failure-like phenotype
that had depressed bioenergetics dominated by glycolysis.
FASN Transgenic Mice Developed Signs of Heart Failure and
Cardiac Lipid Load—The extracellular flux analysis detected a
heart failure-like metabolic substrate use in isolated car-
diomyocytes from Tg-FASN mice. But the method employs
unloaded cardiomyocytes and does not represent the condition
in the loaded myocardium, which functions with real heart
rates. Therefore, we analyzed the cardiac phenotype in vivo.
Our data show that adult FASN transgenic mice developed
signs of heart failure as early as 6months of age, as evidenced by
a significantly decreased left ventricular ejection fraction, car-
diac hypertrophy with dilatation, and increased cardiomyocyte
apoptosis (Fig. 2, A–E). As a control, the body weight of 6
month-old Tg-FASN mice was not different from B6 control
mice (i.e. 34.28 1.02 g and 33.45 0.98 g, respectively;S.D.;
n	 4; p	 0.5909).
The cardiac FASN protein in FASN-expressing mice was
detected by immunoblotting and immunohistology (Fig. 2,
F–H). The FASNprotein level inTg-FASNheartswas increased

2.4-fold (Fig. 2, F and G), which is comparable with the up-
regulated FASN level of failing human hearts (10, 11).
Concomitantly to the increased FASN protein, cardiac FFA
and triacylglycerol contents of Tg-FASN mice with signs of
heart failurewere elevated 2.2- and 2.1-fold, respectively (Fig. 2,
I and J). The cardiac contents ofDAGand ceramides, which can
be induced by palmitate, i.e. the major lipid synthesized by
FASN, were also significantly increased (Fig. 2, K and L). These
lipids could be involved in the heart failure phenotype of Tg-
FASNmice because they trigger a wide spectrum of cardiotoxic
mechanisms, which involves, for example, the excessive forma-
tion of reactive oxygen species, an increased endoplasmic retic-
ulum stress, enhanced apoptosis, and mitochondrial dysfunc-
tion (22, 26). Additionally, increased cardiac contents of DAG
and ceramide could mediate the activation of protein kinase C
(PKC), which further decreases heart function (22, 27, 28).
Thus, FASN transgenic hearts developed signs of heart failure
with cardiotoxic lipid load in addition to the dysfunctional
energy substrate metabolism, which was detected in isolated
cardiomyocytes.
Up-regulation of the Heart Failure-related Cardiac Lipid
Metabolic Process in FASN Transgenic Mice—Whole genome
microarray gene expression profiling further confirmed the
heart failure phenotype of Tg-FASN hearts by demonstrating
the significant up-regulation of the heart failure-related cardiac
lipid metabolic process (Fig. 3A). A similar induction of those
adipogenic genes was also observed when signs of heart failure
were triggered by 6 months of pressure overload (Fig. 3B) (11).
In contrast, cardiac hypertrophy, without signs of heart failure
(11) and induced by 4 weeks of pressure overload, did not up-
regulate the heart failure-related adipogenic gene expression
signature (Fig. 3C). Moreover, cardiac hypertrophy in the
absence of heart failure signs promoted a significantly
decreased expression of two probe sets that detect two enzymes
of fatty acid biosynthesis, i.e. Scd1 (stearoyl-CoA desaturase-1)
and Acly (ATP citrate lyase) (Fig. 3C). Thus, a heart failure-
related adipogenic gene expression signature accompanied the
onset of heart failure signs in FASN transgenic mice.
Heart Failure-related Adipogenic Genes Triggered by FASN
Are Pparg Targets—In search of FASN-induced pathomecha-
nisms, we focused on the adipogenic and heart failure-promot-
ing transcription factor, Pparg (29, 30), because (i) palmitate,
the major lipid synthesized by FASN, enhances the activity of
Pparg (31), and (ii) adipogenic genes induced by FASN are
Pparg targets (32), which are similarly up-regulated by Pparg
FIGURE 2. FASN transgenicmice developed signs of heart failure and car-
diac lipid load. A, decreased left ventricular ejection fraction of 6-month-old
Tg-FASNmice. B, histological analysis of a Tg-FASN heart compared with a B6
heart (bar, 2mm). C, increased heart weight-to-body weight ratio of Tg-FASN
mice. D and E, increased number of TUNEL-positive cardiomyocytes of Tg-
FASN hearts. E shows representative immunohistological sections (bar, 20
m). The data shown are themean S.D., n	 5; ***, p 0.0001 (A, C, andD).
F–H, detection of the cardiac FASN protein levels by immunoblotting (IB) (F
and G) and immunohistology (H) relative to the B6 control (bar, 40 m). F
shows quantitative data that were obtained by densitometric scanning of
immunoblots (S.D.,n	4; ***,p	0.0005). I–L, cardiac FFA (I), triacylglycerol
(TAG) (J), DAG (K), and total ceramide (L) contents of Tg-FASNmice relative to
non-transgenic B6 controls (S.D., n 	 5; ***, p 	 0.0006 (I), 0.0004 (J), and
0.0001 (K); **, p	 0.0028). Histology experiments are representative of four
different mice/group (B and H).
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overexpression in the mouse heart (29). Similarly, the treat-
ment of ApoE/ mice for 2 months with the Pparg agonist,
rosiglitazone, also significantly up-regulated those heart fail-
ure-related adipogenic Pparg target genes, which were induced
by FASN (Fig. 3D). As a control, rosiglitazone promoted signs of
heart failure in ApoE/ mice (cf. Fig. 4, F–I). These findings
demonstrate that the heart failure-related adipogenic gene sig-
nature induced by Tg-FASN and chronic pressure overload is
also triggered by direct Pparg activation with rosiglitazone.
Down-regulation of Endogenous Fasn Reveals a Causal Rela-
tionship between Fasn and Pparg Activation in Promoting Car-
diac Dysfunction—Next, we investigated the impact of Fasn on
Pparg-induced cardiac dysfunction, and we knocked down the
endogenously expressed Fasn by RNAi in rosiglitazone-treated
ApoE/mice. Inhibition ofFasn by lentiviral transduction of a
Fasn-specific miRNA (Fig. 4, A–D) retarded the development
of rosiglitazone-induced cardiac lipid load (Fig. 4E) and signs of
rosiglitazone-induced heart failure (Fig. 4,F–I). Together, these
data confirmed the causal relationship between Fasn and
enhanced Pparg activation in promoting cardiotoxicity and
cardiac dysfunction.
GRK2 Inhibition by GRKInh in FASN Transgenic Mice—In
view of the central role of FASN, the inhibition of FASN would
be a straightforward treatment approach. However, FASN is an
essential enzyme that has indispensable functions in energy
homeostasis, membrane biology, and neurogenesis, which pre-
clude long term FASN inhibition in vivo (10, 33, 34). We there-
fore searched for an alternative strategy to target the dysfunc-
tional cardiac substrate metabolism. We focused on the
inhibition of GRK2, which is a well established means of
cardioprotection (12, 35). Furthermore, GRK2 inhibition
enhances the ERK cascade (12), which promotes (partial) inac-
FIGURE 3. Up-regulation of the heart failure-related cardiac lipid meta-
bolic process in FASN transgenic mice. A, microarray gene expression pro-
filing identified significantly up-regulated heart failure-related genes of the
lipid metabolic process in hearts of 6-month-old Tg-FASN mice compared
with B6mice. B, heart failure-related adipogenic gene signature was similarly
detected in 10-month-old B6 mice with heart failure induced by 6months of
AAC compared with age-matched sham controls (Sham-6mo). C, adipogenic
genes were not significantly up-regulated in 5-month-old B6 mice with car-
diac hypertrophy induced by 1 month of ACC (cardiac hypertrophy) in the
absence of heart failure signs compared with the sham control (Sham-1mo).
D, significantly up-regulated genes of the lipidmetabolic process in hearts of
8-month-old ApoE/mice with 2 months of Pparg activation with rosiglita-
zone compared with untreated ApoE/mice. The probe sets were catego-
rized into genes involved in lipid synthesis, storage, oxidation (Oxid.), and
adipocyte (Adipoc.) differentiation. The statistical significance of themicroar-
ray datawas evaluated using signal intensity values of probe sets (*, p 0.05;
**, p  0.01; ***, p  0.001 versus the respective control; S.D., n 	 2 gene
chips per group, cRNA pooled from four mice/gene chip).
FIGURE4.Down-regulationofendogenousFasn revealsacausal relation-
ship between Fasn and Pparg activation in promoting cardiac dysfunc-
tion. A and B, stable integration of lentiviral miFasn-DNA into the genomic
DNA of ApoE/ mouse hearts (H1, H2), kidneys (K1, K2), and livers (L1, L2)
isolated 2 months after lentiviral transduction. Control DNA (cont. DNA) was
isolated from an ApoE/ mouse. B, genomic integration of lentiviral DNA
was quantified by quantitative PCR (S.D.; n	 6; ***, p 0.001; *, p 0.05
versus heart). C, lentivirus-mediated delivery ofmiFasn decreased the expres-
sion of Fasn in hearts of ApoE/mice with 2 months of Pparg activation by
rosiglitazone (S.D.; n 	 3; **, p 	 0.0029). D and E, immunohistological
detection of Fasn (D) with anti-Fasn antibodies (anti-Fasn), and total lipids by
Oil Red O staining (E) in cardiac sections of ApoE/mice after 2 months of
Pparg activation and transduction of a control lentivirus (miCon) or lentiviral
delivery of miFasn (bar, 40 m). F, lentivirus-mediated delivery of miFasn
normalized the enhanced cardiomyocyte apoptosis of ApoE/ mice that
was triggered by Pparg activation (S.D.; n 	 3; **, p 	 0.0031). The right
panels show representative immunohistology images of TUNEL staining (bar,
20 m). G, viral transduction of ApoE/ mice with a lentivirus that targets
Fasn by RNAi (miFasn) retarded the increase in the heart weight-to-body
weight ratio that was induced by 2months of Pparg activation with rosiglita-
zone (S.D.; n 	 6; **, p 	 0.0011). H, histological analysis of hearts from
8-month-old ApoE/ mice isolated after 2 months of Pparg activation and
transduction of a control lentivirus (miCon) or miFasn (bar, 2 mm). I, left ven-
tricular ejection fraction of ApoE/mice after 2 months of Pparg activation
and transduction of a control lentivirus (miCon) or miFasn (S.D.; n	 6; ***,
p	 0.0002). Histology experiments are representative of four differentmice/
group (D, E, and H).
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tivation of Pparg (36). In agreement with heart failure patients
(37), the GRK2 protein levels were significantly up-regulated
(i.e. 1.81  0.12-fold) in Tg-FASN hearts with signs of heart
failure relative to the B6 controls (Fig. 5A).
To inhibit GRK2 in vivo, we used a GRKInh derived from the
first intracellular loop of the 2 adrenergic receptor (12, 17).
We used transgenicmicewithmyocardium-specific expression
of GRKInh, which were established previously (12). The
GRKInh peptide interacted specifically with GRK2 in heart tis-
sue extracts from Tg-GRKInh/FASNmice as demonstrated by
co-enrichment, whereas the amount of GRK5 co-enrichedwith
GRKInh-specific antibodies was below the limit of detection
(Fig. 5B). Quantitative assessment of the GRK2-GRKInh inter-
action indicated that 83.6  4.2% of the total cardiac GRK2
protein was captured by GRKInh affinity enrichment, whereas
the amount of GRK5 protein bound to GRKInh was less than
20% (i.e. 18.9  2.2%) of the total cardiac GRK5 content (Fig.
5C).
The functional effects of GRK2 inhibition in transgenic Tg-
GRKInh/FASN hearts were analyzed by the immunofluores-
cence detection ofArrb1, which translocates to phosphorylated
membrane-spanning receptors as a direct consequence of
GRK2-mediated phosphorylation (Fig. 5D). In agreement with
an increased GRK2 activity, immunofluorescence analysis
detected the substantial membrane localization of Arrb1 in a
cardiac section from a Tg-FASNmouse with signs of heart fail-
ure (Fig. 5D, left panel). In contrast, the double transgenic Tg-
GRKInh/FASN heart section showed a largely cytoplasmic
localization of Arrb1 as evidenced by co-localization with the
cytosolic p38MAPK (Fig. 5D, right panel). These findings indi-
cate that GRKInh interacts with GRK2 in hearts from double
transgenic Tg-GRKInh/FASN mice. As a consequence of the
GRKInh-GRK2 interaction, the enhanced GRK2-mediated
Arrb1 membrane translocation could be blunted.
GRK2 Inhibition by GRKInh Prevents the Dysfunctional Car-
diac Energetics of FASNTransgenic Cardiomyocytes—Wechar-
acterized the substrate metabolism of isolated neonatal car-
diomyocytes from double transgenic Tg-GRKInh/FASN mice
compared with single transgenic Tg-FASN mice. Under basal
conditions, the presence of GRKInh retarded the premature
appearance of an adult-like metabolic phenotype with an
increased baseline OCR of Tg-FASN cardiomyocytes (Fig. 6, A
and B). Concomitantly, the increased -oxidation of Tg-FASN
cardiomyocytes under basal conditions was also retarded in
double transgenic Tg-GRKInh/FASN cardiomyocytes (Fig. 6,A
and C). Notably, the extent of -oxidation of Tg-GRKInh/
FASN double transgenic cardiomyocytes was not significantly
different from that of the B6 control, i.e. 6.0 1.0% versus 5.4
1.7%, respectively (Fig. 6, A and C). Moreover, under the 3F
protocol, GRKInh retarded the shift to a heart failure-like met-
abolic phenotype of Tg-FASN cardiomyocytes, which is char-
acterized by predominant glycolysis and decreased-oxidation
(Fig. 6, A–E). Similarly to non-transgenic B6 controls, the Tg-
GRKInh/FASN cardiomyocytes shifted to an adult-like pheno-
type, which is characterized by an increased baseline OCR and
an elevated -oxidation (Fig. 6, A–E).
The improved metabolic profile of Tg-GRKInh/FASN car-
diomyocytes was accompanied by a resensitization of adi-
ponectin receptor protein 1 (Adipor1)-mediated signaling (Fig.
6F), which is desensitized by GRK2 in the ischemic heart (14).
Notably, the inhibition of GRK2 in Tg-GRKInh/FASN car-
diomyocytes led to a significantly increased protein level of acti-
vated phospho-Prkaa upon adiponectin stimulation, whereas
the adiponectin-stimulated signal was largely blunted in Tg-
FASN cardiomyocytes (Fig. 6F). This finding could be relevant
because Adipor1 and its target AMP-activated protein kinase
FIGURE 5. GRK2 inhibition by GRKInh in FASN transgenic mice. A, cardiac
up-regulation of the GRK2 protein level in Tg-FASN relative to B6 hearts was
detected by immunoblotting (IB) with GRK2-specific antibodies (n	 4 mice/
group). The lower panel is a control immunoblot detecting Gnb. The right
panel shows the quantitative immunoblot evaluation (S.D., n	 4). B, immu-
noaffinity enrichmentofGRKInh (AP,)withGRKInh-specific antibodies from
Tg-GRKInh/FASN hearts, and immunoblot detection (IB) of co-enriched GRK2
protein (left panel) andGRK5protein (right panel). The control experiment (AP,
) applied an affinity matrix with immobilized control IgG. The lower panels
show immunoblot detection of enriched GRKInh. C, quantitative assessment
of the GRKInh-GRK interaction. GRK2 and GRK5 protein levels were deter-
mined by immunoblotting with GRK2-specific and GRK5-specific antibodies,
respectively, of cardiac lysates from Tg-GRKInh/FASNmice before (total) and
after (not bound to GRKInh) incubation with an affinity matrix with immobi-
lized anti-GRKInh antibodies. The left andmiddle panels present data evalua-
tion from three independent experiments (S.D., n	 3), and the right panels
show representative immunoblots. D, immunofluorescence co-localization
of Arrb1 with p38 MAPK in cardiac sections from Tg-FASN and Tg-GRKInh/
FASNmice (bar, 20m). Arrb1was detectedwith affinity-purifiedmouse anti-
Arrb1 antibodies followed by F(ab)2 fragments of Alexa Fluor 546-labeled
(red) secondary antibodies, andp38wasdetectedwith affinity-purified rabbit
anti-p38 MAPK antibodies followed by F(ab)2 fragments of Alexa Fluor 488-
labeled (green) secondary antibodies. Cell nuclei were stained with DAPI
(blue). Immunofluorescence experiments are representative of four different
mice/group.
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(Prkaa) could protect against palmitate-induced toxicity (15,
16).
GRK2 Inhibition Retards the Development of Heart Failure
Signs in Tg-FASN Mice—The improved substrate metabolism
upon GRK2 inhibition was also reflected in vivo, in adult
murine hearts. The presence of GRKInh in double transgenic
Tg-GRKInh/FASN hearts compared with single transgenic Tg-
FASN hearts led to a significantly decreased total FFA and tria-
cylglycerol load compared with single transgenic Tg-FASN
hearts (Fig. 7, A and B).
The decreased lipid load of Tg-GRKInh/FASN hearts was
accompanied by a significantly decreased cardiac expression of
the acetyl-CoA carboxylase  (Acaca), which mediates an
essential step of fatty acid synthesis by catalyzing the conver-
sion of acetyl-CoA into malonyl-CoA (Fig. 7C). Notably,
GRKInh largely prevented the up-regulation of Acaca, i.e. a
gene up-regulated by hypoxia (38), which was commonly trig-
gered at the onset of heart failure induced by Tg-FASN, pres-
sure overload, and Pparg (Fig. 7C and cf. Fig. 3, A, B, and D).
Although the expression of the human FASN transgene was
not significantly altered between single transgenic Tg-FASN
and double transgenic Tg-GRKInh/FASN hearts (Fig. 7D, left
panel), GRKInh led to a significantly decreased expression of
the endogenous murine Fasn gene, which is also a hypoxia-
induced Pparg target (39), and shows up-regulated expression
in Tg-FASN hearts with signs of heart failure (Fig. 7D, right
panel, and cf. Fig. 3A). Concomitantly, the total cardiac FASN/
Fasn protein level of Tg-GRKInh/FASN hearts was significantly
decreased relative to that in Tg-FASN hearts (Fig. 7E).
Together, these experiments show that GRK2 inhibition
retards the FASN-induced dysfunction of the cardiac substrate
metabolism and lipid overload. Concomitantly with the
FIGURE 6. GRK2 inhibition by GRKInh prevents the dysfunctional cardiac energetics of FASN transgenic cardiomyocytes. A and B, development of
dysfunctional cardiomyocyte energetics of FASN transgenic cardiomyocytes was retarded in double transgenic mice that co-expressed the GRK2-inhibitor,
GRKInh. Real timemeasurements of OCR and ECAR of neonatal cardiomyocytes isolated from FASN transgenic (Tg-FASN), double transgenic Tg-GRKInh/FASN,
and non-transgenic B6 mice were performed under basal conditions (left panels) and after treatment with the 3F protocol (right panels). The OCR and ECAR
values normalized to the baseline (A), and the absolute values of OCR and ECAR (B) are presented. C–E, Etomoxir (Etom.)-blocked fraction of OCR, which
represents fatty acid -oxidation (C), the 2-deoxyglucose (2-DG)-blocked fraction of ECAR, which represents glycolysis (D), and the ratio of glycolysis/-
oxidation (E)weredeterminedwith cardiomyocytes isolated fromTg-FASN, Tg-GRKInh/FASN, B6, andTg-GRKInhmice. Thedata are shownas themeans S.D.;
n	 6 technical replicates (A and B) and n	 3 biological replicates (C–E); *, p 0.05; **, p 0.01 and ***, p 0.001 versus Tg-FASN. F, cardiomyocytes from
Tg-GRKInh/FASN (lanes 3 and 4) mice showed significant adiponectin (Adipoq)-stimulated activation of Prkaa relative to Tg-FASN cardiomyocytes (lanes 1 and
2). Cardiomyocytes (3F protocol) were stimulatedwithout () andwith () globular domain adiponectin (2g/ml) for 60min, and the activation of Prkaawas
determined by immunoblotting (IB) with phospho-Prkaa (p-Prkaa)-specific antibodies. The left panel presents quantitative data from four independent
experiments (S.D.; n	 4; ***, p 0.0001), and themiddle and right panels show representative immunoblots.
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decreased lipid load, the development of signs of heart failure,
such as cardiac dysfunction, cardiac hypertrophy, cardiac ATP
depletion, and FASN/Fasn-mediated cell death, was signifi-
cantly retarded (Fig. 7, F–I).
GRK2 Inhibition Promotes ERK Axis-dependent Inhibition of
Pparg Transcriptional Activity—We investigated the mecha-
nism that accounts for GRK2 inhibition-mediated protection
against FASN-induced cardiolipotoxicity and focused on the
interrelationship between GRK2 inhibition-mediated ERK axis
activation and the inactivation of Pparg. Several lines of evi-
dence support such a relationship. (i) The expression of several
heart failure-related Pparg targets such as adiponectin (Adi-
poq), resistin (Retn), and uncoupling protein 1 (Ucp1) is down-
regulated by ERK-dependent inactivation of Pparg, partially by
involving serine 273phosphorylation (36, 40). (ii)GRK2 inhibition
enhances the activation of the ERKcascade (12, 41). (iii) Addition-
ally, the reversal of palmitate toxicity can be achieved by ERK acti-
vation, e.g. triggered by AMPK signaling (16), i.e. the signaling
pathway that was re-sensitized by GRK2 inhibition (cf. Fig. 6F).
Conversely, excess palmitate down-regulated the ERK axis (16).
FIGURE 7. GRKInh retards the development of heart failure signs in Tg-FASNmice and promotes ERK axis-dependent inhibition of Pparg transcrip-
tional activity. A and B, cardiac FFA (A) and triacylglycerol (TAG) (B) contents of Tg-FASNmice relative to double transgenic Tg-GRKInh/FASN, non-transgenic
B6, and single transgenic Tg-GRKInhmice (S.D., n	 5; *, p 0.05 versus Tg-FASN and Tg-GRKInh; **, p 0.01 versus Tg-FASN; ***, p 0.001 versus Tg-FASN).
C, cardiac Acaca expression in Tg-FASN, double transgenic Tg-GRKInh/FASN, B6, and Tg-GRKInh mice (S.D. n	 5; ***, p 0.001 versus Tg-GRKInh/FASN, B6,
and Tg-GRKInh hearts). D, cardiac expression of transgenic FASN (left panel) ( S.D., n 	 5; ***, p  0.001 versus B6), and expression of the endogenously
expressed murine Fasn (right panel) (S.D.; n 	 5; ***, p  0.001 versus Tg-GRKInh/FASN and B6). E, immunoblot (IB) detection of the FASN/Fasn protein in
cardiac tissue extracts from Tg-FASN relative to Tg-GRKInh/FASNmice (S.D.; n	 5 hearts/group; **, p	 0.0016). F–H, left ventricular ejection fraction (F), the
heart weight-to-bodyweight ratio (G), and the cardiac ATP content (H) of Tg-FASNmice relative to double transgenic Tg-GRKInh/FASNmice and age-matched
B6 controls ( S.D., n	 5; *, p 0.05; **, p 0.01 and ***, p 0.001 versus Tg-FASN). I, number of TUNEL-positive cardiomyocytes ( S.D., n	 5; ***, p 0.001
versus Tg-FASN). The right panel shows representative immunohistological sections of TUNEL staining (bar, 20 m). J, immunohistological detection of
activated phospho-ERK1/2 in cardiac sections of a Tg-FASNmouse relative to a Tg-GRKInh/FASNmouse (bar, 40m). Histology experiments are representative
of four differentmice/group. K, immunoblot detection of activated phospho-ERK1/2 (upper panel) and total ERK1/2 (lower panel) in cardiac tissue extracts from
Tg-FASN relative to Tg-GRKInh/FASNmice (n	 4 hearts/group). L, immunoblot detection of pS273-Pparg (upper panel) and total Pparg (lower panel) in cardiac
tissue extracts from Tg-FASN and Tg-GRKInh/FASNmice (n	 4 hearts/group).M andN, immunoblot detection (M) of pS273-Pparg (upper panel), pS112-Pparg
(middle panel), and Pparg (lower panel), respectively, and Pparg activity of nuclear extracts (N) from Tg-FASN relative to Tg-GRKInh/FASN cardiomyocytes (3F
protocol) treatedwithout () orwith () theMEK inhibitor PD0325901 (0.5M) (S.D.;n	4; ***,p0.001).O, cardiac expressionof heart failure-relatedPparg
target genes in Tg-FASN, double transgenic Tg-GRKInh/FASN, and B6 control mice (S.D.; n	 4; ***, p 0.001 versus Tg-GRKInh/FASN and B6).
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In agreement with palmitate-mediated inhibition of ERK
(16), the cardiac content of activated phospho-ERK1/2 was low
in Tg-FASN hearts relative to double transgenic Tg-GRKInh/
FASN hearts (Fig. 7, J and K). Notably, GRKInh enhanced the
activation of ERK2 (Fig. 7K), which is cardioprotective and pro-
tects the myocardium against ischemic injury (42). Concomi-
tantly with enhanced ERK1/2 activation, serine 273-phosphor-
ylated Pparg was increased in double transgenic Tg-GRKInh/
FASN hearts relative to Tg-FASN hearts (Fig. 7L).
In agreement with the ERK-dependent inactivation of Pparg
(36, 40, 43), the enhanced phosphorylation of Pparg on serine
273 and serine 112 of double transgenic Tg-GRKInh/FASN car-
diomyocytes was accompanied by a significantly decreased
Pparg transcription factor DNA binding activity compared
with that of Tg-FASN cardiomyocytes (Fig. 7, M and N). The
decreased Pparg activity of Tg-GRKInh/FASN cardiomyocytes
was dependent on an activated ERK axis because the MEK
inhibitor PD0325901 blunted the phosphorylation of Pparg on
serine 273 and serine 112 and led to a significant up-regulation
of the Pparg transcriptional activity of Tg-GRKInh/FASN car-
diomyocytes (Fig. 7,M and N).
ConcomitantlywithPparg inhibition, the expression of ERK-
regulated, heart failure-relatedPparg targets (i.e. Ucp1 andAdi-
poq) was significantly lower in double transgenic Tg-GRKInh/
FASN hearts compared with Tg-FASN hearts (Fig. 7O).
Concordantly with decreased signs of heart failure, GRKInh
also led to a significantly decreased expression of the heart fail-
ure marker and Pparg target gene, Retn (Fig. 7O). Because Adi-
poq andRetn are heart failure-related Pparg targets (44, 45) that
are induced by serine 273 phosphorylation-deficient PPARG-
S273A (40), these data are compatible with the notion that car-
dioprotectiveGRK2 inhibition could involve the suppression of
Pparg-dependent cardiolipotoxic gene expression by enhanced
ERK-mediated serine 273 phosphorylation and the inactivation
of Pparg.
Inhibition of Fasn Lowers the Cardiolipotoxicity Induced by
Serine 273 Phosphorylation-deficient PPARG-S273A—We ana-
lyzed the impact of phosphorylation-deficient PPARG-S273A
on cardiomyocyte function. Our experiments showed that both
cardiomyocyte FFA content and the Fasn protein were trig-
gered by PPARG activated with the PPARG agonist rosiglita-
zone and by PPARG-S273A (Fig. 8,A,C, andD). These data are
in agreement with those from previous studies, which have
shown that PPARG serine 273 dephosphorylation can enhance
the expression of Fasn (46).
Concomitantly with the FFA load, cardiomyocyte dysfunc-
tion developed as evidenced by a significantly decreased car-
diomyocyte ATP content induced either by rosiglitazone-acti-
vated PPARG or PPARG-S273A, respectively (Fig. 8B). The
inhibition of Fasn by RNAi (Fig. 8, C and D) led to significantly
decreased cardiomyocyte FFA content and largely prevented
the decrease in cardiomyocyte ATP (Fig. 8,A and B). Together,
these findings provide evidence that PPARG-S273A deterio-
rates cardiomyocyte function by regulating Fasn.
GRK2 Inhibition Retards the Up-regulation of the Heart Fail-
ure-related Ucp1 and Mitochondrial Uncoupling—In search of
additional heart failure-promoting ERK-controlled Pparg tar-
get genes, we focused onUcp1 (36, 47), which exertsmitochon-
drial uncoupling, a major metabolic feature of the failing heart
metabolism (9). GRK2 inhibition by GRKInh led to a decreased
cardiacUcp1 expression andprotein level inTg-GRKInh/FASN
mice relative to Tg-FASNmice (Fig. 9A and cf. Fig. 7O). More-
over, cardiomyocytes from Tg-GRKInh/FASN mice showed a
significantly decreased oligomycin-insensitiveOCR (ameasure
of mitochondrial uncoupling) compared with Tg-FASN car-
diomyocytes (Fig. 9B). Conversely, the inhibition of the ERK
axis in Tg-GRKInh/FASN cardiomyocytes significantly in-
creased theUcp1 protein andmitochondrial uncoupling (Fig. 9,
B and C). These findings indicate that GRK2 inhibition
decreased Ucp1-dependent mitochondrial uncoupling in Tg-
GRKInh/FASN cardiomyocytes by enhanced activation of the
ERK axis.
Transgenic Tg-UCP1 Mice Developed Signs of Heart Failure
and IncreasedMitochondrial Uncoupling—To analyze whether
an increased cardiac UCP1 level contributed to heart failure
FIGURE 8. Inhibition of Fasn decreases cardiolipotoxicity induced by ser-
ine 273 phosphorylation-deficient PPARG-S273A. A and B, neonatal rat
cardiomyocytes were transfected with PPARG or PPARG-S273A mutant and
incubated in the absence () or presence () of rosiglitazone (Rosiglit., 5M),
and Fasn was inhibited by RNAi (siFasn) as indicated. The free fatty acid (A)
andATP (B) contents of cardiomyocytesweredetermined (S.D.;n	4; *,p
0.05; **, p 0.01; ***, p 0.001 versus controls transfected with stealth con-
trol RNAi (); Dunnett’s multiple comparison test). C, immunoblot detection
of Fasn (upper panel) and PPARG (middle panel) in cardiomyocyte lysates. The
lower panel is a control immunoblot detecting (IB) Gnb. D, immunofluores-
cence localization of Fasn (red) and the transmembrane-spanning AT1 recep-
tor (AT1R; green) in cardiomyocytes without (Control) or with transfection of
PPARG, PPARG-S273A, siFasn, and treatment with rosiglitazone (Rosiglit.) as
indicated. Fasn was detected with affinity-purified rabbit anti-Fasn antibod-
ies followed by F(ab)2 fragments of Alexa Fluor 546-labeled secondary anti-
bodies, andAT1Rwas detectedwith affinity-purified rat anti-AT1R antibodies
followed by F(ab)2 fragments of Alexa Fluor 488-labeled secondary antibod-
ies. Cell nuclei were stainedwithDAPI (blue; bar, 20m). The immunofluores-
cence data are representative of four independent experiments.
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pathogenesis in vivo, we generated Tg-UCP1 mice with myo-
cardium-specificUCP1 expression (Fig. 10,A and B). Immuno-
blot detection confirmed the increased cardiacUCP1protein in
Tg-UCP1 (Tg-6) mice relative to non-transgenic B6 controls
(Fig. 10C). In addition to the Tg-6 line, we also used Tg-11
offspring with lower UCP1 protein levels (Fig. 10D).
Aged Tg-UCP1 mice from the Tg-6 line developed cardiac
dysfunction with a significantly decreased left ventricular ejec-
tion fraction and decreased cardiac ATP content compared
with non-transgenic B6mice, whereas cardiac function param-
eters of the low-expressing Tg-11 line were not significantly
different from B6 controls (Fig. 10, E and F). Concomitantly
with cardiac dysfunction, Tg-UCP1mice showed cardiac dila-
tation and loss of heart muscle, whereas the heart weight-to-
bodyweight ratiowas not significantly different from that in the
B6 controls (Fig 10,G andH). Signs of heart failurewere accom-
panied by a significant up-regulation of the cardiac Fasn protein
in Tg-UCP1 mice compared with non-transgenic B6 controls
(Fig. 10I). The up-regulation of the Fasn protein byUCP1 could
be a consequence of the impaired cardiac function and insuffi-
cient tissue oxygen supply, which could induce Fasn up-regu-
lation because it is a hypoxia-induced gene (39).
The ensuing increase in palmitate may enhance mitochon-
drial uncoupling by the transgenic UCP1 protein. In support of
that notion, Tg-UCP1 cardiomyocytes showed a significantly
increased oligomycin-insensitive (uncoupled) respiration com-
paredwith B6 cardiomyocytes (Fig. 10J). Together, these exper-
iments indicate that the UCP1 protein could have a major role
in the depressed substratemetabolism of a failing heart because
up-regulated UCP1 could account for an enhanced palmitate-
triggered uncoupled respiration upon FASN induction. Under
those conditions, GRK2 inhibition by GRKInh could confer
several modes of cardioprotection as follows: (i) by counteract-
ing mitochondrial uncoupling via ERK activation-mediated
down-regulation ofUCP1 (36); and (ii) by decreasing theFASN-
triggered lipid load, which involves, e.g. down-regulation of
hypoxia-induced Pparg targets,Acaca and Fasn, and the resen-
sitization of Prkaa.
Inhibition of Ucp1 Counteracts PPARG-S273A-induced
Cardiolipotoxicity—The mechanism of ERK-mediated down-
regulation of the Pparg target, Ucp1, is not completely under-
stood (36, 47).Ucp1 is a Pparg target that is highly up-regulated
in Tg-FASN and pressure overload-induced heart failure mod-
els, and by direct Pparg activation with rosiglitazone (cf. Fig. 3).
Low ERK axis activity in these models could mediate stabiliza-
tion of transcriptional cofactors that are necessary for Ucp1
induction, i.e. PGC1a or PRDM16 (36). Moreover, recent data
have shown that PPARG-S273 dephosphorylation can also
enhance the recruitment ofPGC1a as a transcriptional cofactor
involved in Ucp1 induction (46). To analyze the interplay
between Ucp1 and PPARG-S273A-mediated cardiolipotoxic-
ity, we inhibitedUcp1 byRNAi. The inhibition ofUcp1 led to an
increased ATP content of cardiomyocytes with rosiglitazone-
activated PPARG and with PPARG-S273A expression, while
concomitantly decreasing the cardiomyocyte FFA content (Fig.
10K). These findings obtained with Ucp1 are analogous to the
data obtained with Ucp2, which showed the following: (i) the
Ucp2 knock-out decreased the cellular lipid content of pancre-
atic islets as a consequence of higher palmitate oxidation (48);
(ii)Ucp1knockdownattenuated the free fatty acid-inducedapo-
ptosis of cardiomyocytes (49); and (iii) conversely, Ucp2 over-
expression decreased the cardiomyocyte ATP levels (50).
Taken together, the data are compatible with the notion that
Ucp1 exerts a detrimental role in cardiolipotoxicity, as trig-
gered, for example, by Pparg activation with rosiglitazone
and/or serine 273 dephosphorylation. However, the inhibition
of Ucp1 could counteract such cardiotoxic effects.
Cardioprotective GRK2 Inhibition Requires an Intact ERK
Axis—We further investigated the impact of ERK activation on
cardioprotective GRK2 inhibition and applied the dual-specific
GRK2 and ERK cascade inhibitor, RKIP (21). RKIP transgenic
mice with myocardium-specific expression of the human RKIP
(PEBP1) were previously generated and characterized (12).
RKIP and GRKInh transgenic hearts display similar inhibition
of GRK2 (12). Similarly, isolated neonatal cardiomyocytes of
RKIP transgenic and GRKInh transgenic mice showed a com-
parable enhancement of the isoproterenol-stimulated cAMP
response (Fig. 11A). This observation confirmed that the two
different GRK2 inhibitors were expressed at equivalent levels
with regard to the sensitization of the -adrenergic receptor
response. However, in contrast to GRKInh, transgenic hearts
that expressed the dual-specific GRK2/ERK cascade inhibitor,
RKIP,werecharacterizedbyasignificantlydecreasedphosphor-
ylation of Pparg on serine 273 (Fig. 11, B and C), which is ERK-
dependent (36).
We next determined the expression of cardiac Pparg targets
of RKIP transgenic hearts because the inhibition ofPparg serine
273 phosphorylation inducesPparg target gene expression (36).
Gene expression analysis revealed the significant up-regulation
of heart failure-related Pparg targets (Fig 11D). Some of those
highly up-regulated heart failure genes, such as adipsin (Adn),
adiponectin (Adipoq), fatty acid synthase (Fasn), resistin (Retn),
and uncoupling protein-1 (Ucp1), are reportedly induced by the
inhibition of ERK and/or serine 273 dephosphorylation of
Pparg (36, 40, 46), which was triggered by RKIP (cf. Fig. 11, B
and C). In agreement with heart failure-related adipogenic tar-
FIGURE 9. GRK2 inhibition retards up-regulation of heart failure-related
Ucp1 andmitochondrial uncoupling. A, immunoblot (IB) detection of Ucp1
protein in heart tissue extracts of Tg-FASN relative to Tg-GRKInh/FASN mice
(n	 4 hearts/group). The lower panel shows a control immunoblot detecting
Gnb. B, increased oligomycin-insensitiveOCRof Tg-FASN cardiomyocytes rel-
ative to Tg-GRKInh/FASN cardiomyocytes (3F) treated for 72 h without () or
with () the MEK inhibitor PD0325901 (S.D.; n 	 4; *, p  0.05 versus
TgGRKInh/FASN(); **,p0.01 versus TgFASN). BaselineOCR (3F) of Tg-FASN,
Tg-GRKInh/FASN, and Tg-GRKInh/FASN (PD) was 13.68 0.98, 22.73 2.18,
and 18.09 2.62 pmol/min per g of protein, respectively (S.D.; n	 4). C,
immunoblotdetectionofUcp1proteinof Tg-FASN cardiomyocytes relative to
Tg-GRKInh/FASN cardiomyocytes treated for 72 h without () or with ()
PD0325901 (S.D.; n 	 4; *, p  0.05 versus Tg-GRKInh/FASN (); ***, p 
0.001 versus Tg-FASN). The right panels show a representative immunoblot
experiment.
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get gene up-regulation, cardiac lipid load developed, and car-
diac dysfunction became evident in hearts of aged RKIP trans-
genic mice (Fig. 11, E–H) (12). In vitro data documented the
dysfunctional cardiomyocyte energetics of RKIP transgenic
cardiomyocytes compared with the normal metabolism of
GRKInh transgenic cardiomyocytes (Fig. 11, I–M). Taken
together, our data strongly suggest that an intact ERK axis is
required for GRK2 inhibition-dependent protection against
dysfunctional metabolic substrate use.
GRK2 Inhibition Retards the Development of Heart Failure
Signs, Cardiac Lipid Load, and Pparg Target Gene Induction in
a Pressure Overload-induced Heart Failure Model—Thus, we
have presented evidence for GRKInh-mediated protection of
Tg-FASN hearts. However, up-regulation of the Pparg-depen-
FIGURE 10. Tg-UCP1mice developed signs of heart failure andmitochondrial uncoupling. A, transgenic vector used for the generation of Tg-UCP1mice
with myocardium-specific UCP1 expression. B, PCR identification of founder mice with stable integration of the UCP1 transgene into the genomic DNA. C and
D, immunoblots (IB) show the detection of UCP1 protein in 6-month-old Tg-UCP1 hearts (Tg-6) relative to age-matched B6 hearts (C), and Tg-11 hearts (D),
respectively (n	 4 hearts/group (C) and n	 3 hearts/group (D); the last lane of D is an additional B6 control). The lower panels show control immunoblots
detecting Gnb. E and F, left ventricular ejection fraction (E) and cardiac ATP content (F) of 6-month-old Tg-UCP1 mice (Tg-6) relative to Tg-11 mice and B6
controls (S.D.; n 	 5; **, p  0.01; ***, p  0.001 versus B6 control; Dunnett’s multiple comparison test). G, heart weight-to-body weight ratio of Tg-UCP1
relative to B6 mice (S.D.; n	 5). H, representative histological section of a 6-month-old Tg-UCP1 heart relative to an age-matched B6 control (bar, 2 mm).
Histology experiments are representative of four differentmice/group. I, immunoblot detection of Fasnprotein in cardiac tissue extracts fromTg-UCP1 relative
to B6mice (S.D.;n	 4). The left panel shows a representative immunoblot detection for Fasn. J, increasedoligomycin-insensitiveOCRof Tg-UCP1 cardiomyo-
cytes relative to B6 cardiomyocytes (S.D.; n 	 4 biological replicates; 3F protocol). The right panel shows baseline OCR values. K, FFA (left panel) and ATP
contents (middle panel) of isolated neonatal cardiomyocytes from B6 mice after transfection without () or with () PPARG, PPARG-S273A, siUcp1, and
treatment with rosiglitazone (rosiglit.) as indicated (S.D.; n	 4; *, p 0.05; **, p 0.01; ***, p 0.001 versus control transfected with stealth control RNAi
(); Dunnett’s multiple comparison test). The right panels show immunoblot detection of Ucp1 and PPARG.
GRK2 Inhibition Retards Cardiometabolic Dysfunction
2594 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 6•FEBRUARY 5, 2016
 at U
ZH
 H
auptbibliothek / Zentralbibliothek Zuerich on A
ugust 26, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
dent lipid metabolic process is also a characteristic feature of
heart failure models that imitate major risk factors of patients
such as chronic pressure overload (cf. Fig. 3B and Ref. 11). We
therefore analyzed the effect of GRKInh on the cardiac lipid
metabolism in a chronic pressure overload-induced heart fail-
ure model imposed by long term (6 months) AAC.
In agreement with previous data (12), AAC promoted car-
diac hypertrophy with dilatation in non-transgenic mice,
whereas Tg-GRKInh mice showed a significantly decreased
cardiac hypertrophy (Fig. 12, A and B). The development of
cardiac dysfunction upon AAC, as assessed by the left ventric-
ular ejection fraction, was also significantly retarded in
Tg-GRKInh mice (Fig. 12C). In addition to the improved car-
diac function, the AAC-stimulated up-regulation of the cardiac
Fasn protein was blunted in Tg-GRKInh mice (Fig. 12D). Con-
comitantly,Oil RedO staining of cardiac sections indicated that
the AAC-triggered lipid load was lower in Tg-GRKInh mice
(Fig. 12E). In agreement with the decreased lipid-induced car-
diolipotoxicity, Tg-GRKInh mice showed a significantly
decreased number of AAC-induced TUNEL-positive car-
diomyocytes compared with the number in non-transgenic
mice with AAC (Fig. 12, F and G).
In view of the decreasedAAC-induced cardiolipotoxicity, we
analyzed the potential effect of GRK2 inhibition on the Pparg-
inhibitory serine 273 phosphorylation. Immunoblot detection
indicated an increased cardiac content of serine 273-phosphor-
ylated Pparg of Tg-GRKInh hearts with AAC compared with
non-transgenic B6 mice with AAC (Fig. 12, H and I). The
increased level of Pparg-inhibitory serine 273 phosphorylation
was accompanied by a significantly lower expression of heart
failure-related Pparg targets, which are blunted by ERK activa-
tion and/or ERK-dependent Pparg serine 273 phosphorylation,
i.e. Ucp1, Adipoq, and Retn (Fig. 12J). Taken together, cardio-
protective GRK2 inhibition with GRKInh retarded the up-reg-
ulation of heart failure-related and ERK-inhibited Pparg targets
and enhanced Pparg-inhibitory serine 273 phosphorylation.
Down-regulation of Endogenous Ucp1 Retards the Develop-
ment of Cardiac Dysfunction in a Pressure Overload-induced
Heart Failure Model—Although previous studies have pro-
vided evidence for the involvement ofAdipoq and Retn in heart
failure pathogenesis of patients and animal models (44, 45,
51–53), the role ofUcp1 up-regulation in cardiac dysfunction is
less clear. Notably, the onset of heart failure signs in different
heart failuremodels was characterized by a strong cardiacUcp1
up-regulation (cf. Fig. 3), and transgenic expression ofUCP1 in
the heart promoted signs of heart failure (cf. Fig. 10). To inves-
tigate the effect of Ucp1 up-regulation in the AAC-induced
heart failure model, we down-regulated the endogenously
expressed Ucp1 by lentiviral transduction of an miRNA that
targetsUcp1 by RNA interference (Fig. 13,A andB). The down-
regulation ofUcp1 in the AAC-induced heart failure model led
to a small but significant retardation of the development of
FIGURE 11. Cardioprotective GRK2 inhibition requires an intact ERK axis.
A, isoproterenol-stimulated (100nM) cAMP levels of neonatal cardiomyocytes
isolated from RKIP transgenic, GRKInh transgenic, and B6 mice (S.D., n	 3;
***, p  0.001 versus B6). B, immunoblot detection of pS273-Pparg (upper
panel) and total Pparg (lower panel) in cardiac tissue extracts of RKIP trans-
genic mice relative to B6 controls. C, quantitative evaluation of immunoblot
data (S.D., n	 3; ***, p 0.001 and **, p 0.01 versus RKIP; and *, p 0.05
versus B6). D, gene expression data showed up-regulation of the cardiac
Pparg-dependent lipidmetabolic process of 6-month-old Tg-RKIPmice com-
paredwith B6 controls (***, p 0.001; **, p 0.01, *, p 0.05 versusB6). E and
F, cardiac FFA (E) and triacylglycerol (TAG) (F) contents of RKIP transgenic
relative to B6 control hearts (S.D., n 	 5; ***, p 	 0.0006). G, Oil Red O
detection of cardiac lipids in a cardiac section from an RKIP transgenic versus
a B6 control heart (bar, 40 m). Histology experiments are representative of
four different mice/group. H, decreased left ventricular ejection fraction of
RKIP transgenic mice indicates cardiac dysfunction (S.D., n 	 5; ***, p 
0.0001). I and J, real time measurement of OCR (I) and ECAR (J) of neonatal
cardiomyocytes from RKIP transgenic mice was performed under basal con-
ditions and after the creation of an adult-like lipogenic milieu by the 3F pro-
tocol. Neonatal cardiomyocytes from Tg-GRKInh mice were measured under
basal conditions. The relative valuesnormalized to thebaseline (upper panels)
and the absolute values of OCR and ECAR (lower panels) are presented. K–M,
etomoxir (Etom.)-blocked fraction of OCR, which represents fatty acid -oxi-
dation (K), the 2-deoxyglucose (2-DG)-blocked fraction of ECAR, which rep-
resents glycolysis (L), and the ratio of glycolysis/-oxidation (M) are also
given. The data are shown as the means S.D.; n	 6 technical replicates
(I and J) and n	 3 biological replicates (K–M); ***, p 0.001 versus RKIP (K
and M); **, p 0.01 versus RKIP-3F (L) and RKIP (M); and *, p 0.05 versus
RKIP-3F (L and M).
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AAC-induced cardiac dysfunction (Fig. 13C). These findings
provide further evidence (cf. Fig. 10) for the role of Ucp1 up-
regulation in AAC-induced signs of heart failure.
Low Efficacy of GRKInh in Retarding the Cardiac Phenotype
of PPARG-S273A Transgenic Mice—Our data provided evi-
dence that GRK2 inhibition counteracts the dysfunctional car-
diac substrate use of heart failure (at least partially) by ERK-
dependent inactivationofPparg involving serine 273phosphor-
ylation. To further analyze the role of PPARG and a serine 273
phosphorylation-deficient PPARG mutant (PPARG-S273A) in
the heart, we generated transgenicmice withmyocardium-spe-
cific expression of wild-type PPARG and mutated PPARG-
S273A, respectively (Fig. 14A). Histological analysis revealed
that transgenic PPARG-S273A mice developed cardiac hyper-
trophy with dilatation, which was already evident in newborn
mice (Fig. 14B). The dilatation of the PPARG-S273A-express-
ing heart was greater than that of the PPARG-expressing heart
(Fig. 14B), although the cardiac PPARG protein level was com-
parable between the two transgenic groups (Fig. 14C).
Next, we investigated the effect of GRK2 inhibition by
GRKInh and compared single transgenic mice (PPARG-S273A
and PPARG), with double transgenic PPARG-S273A 
GRKInh-expressing and PPARG  GRKInh-expressing mice,
respectively. All four groups of mice showed similar cardiac
PPARG expression (Fig. 14D). Despite having similar PPARG
expression, theGRKInh largely prevented the cardiac hypertro-
phy of PPARG-expressing mice, whereas the effect of GRKInh
on PPARG-S273A-expressing mice was not significant (Fig.
14E). In addition, there was an increased postnatal mortality of
PPARG-S273A-expressing mice compared with wild-type
PPARG-expressing mice (47.8.% versus 9.5%), which was not
rescued by the GRK2 inhibitor (Fig. 14F).
We determined the expression of selected heart failure-re-
latedPparg targets, i.e. Adipoq,Retn, Fasn, andUcp1. The genes
were all significantly up-regulated in the cardiac tissue of
4-week-old PPARG-S273A transgenic mice compared with
non-transgenic B6 mice (Fig. 14G), which confirms the heart
failure-like phenotype of newborn PPARG-S273A transgenic
mice.We found that the effect of GRKInhwas not significant in
reducing the PPARG-S273A-mediated up-regulation of Adi-
poq, Retn, Fasn, and Ucp1 (Fig. 14G). In contrast to PPARG-
FIGURE 12. GRK2 inhibition retards the development of heart failure
signs, cardiac lipid load, and Pparg target gene induction in a pressure
overload-induced heart failure model. A, representative histological sec-
tions of hearts from a 10-month-old B6 mouse (AAC) relative to an age-
matchedGRKInh transgenicmouse (AACGRKInh) after 6months of pressure
overload imposed by AAC. The lower panels show age-matched sham-oper-
ated control hearts, bar, 2mm. B andC, heartweight-to-bodyweight ratio (B),
and the left ventricular ejection fraction (C) of 10-month-old GRKInh trans-
genic mice with 6 months of AAC (AACGRKInh) relative to age-matched
non-transgenic B6 mice with 6 months of AAC (AAC). Age-matched sham-
operated non-transgenic B6 mice (Sham) and sham-operated GRKInh trans-
genic mice (ShamGRKInh) served as controls. Data are shown as the
means S.D., n	 4 (*, p 0.05 versus AACGRKInh; **, p 0.01 versus AAC;
***, p 0.001 versus AAC). D, immunoblot detection of Fasn in cardiac tissue
extracts of 10-month-old B6 mice with 6 months of AAC relative to age-
matched GRKInh transgenicmice with 6months of AAC (n	 4 hearts/group,
left blot). Under the experimental conditions, the Fasn protein (lane 1, A, pos-
itive control of a 10-month-old B6 heart with 6 months of AAC) was not
detectable in cardiac tissueextracts fromsham-operatedB6 (sham) orGRKInh
transgenic mice (n	 2; right blot). The lower panels show control immunob-
lots detecting Gnb. E, Oil RedO staining of cardiac sections from the different
groups ofmice (bar, 40m). Histology experiments are representative of four
different mice/group (A and E). F and G, number of TUNEL-positive car-
diomyocytes (S.D.; n	 4; ***, p 0.001 versusAAC). F shows representative
immunohistological sections of TUNEL staining (bar, 20 m). H and I, immu-
noblot (IB) detection of pS273-Pparg (upper panels) and total Pparg (lower
panels) in cardiac tissue extracts from the different groups of mice (n 	 4
hearts/group (H), and n 	 2 hearts/group (I)). J, expression of heart failure-
related Pparg targets in hearts from 10-month-old B6 mice with 6 months of
AAC (AAC) and age-matched Tg-GRKInh mice with 6 months of AAC
(AACGRKInh) relative to sham-operatedcontrols (S.D.;n	4; ***,p0.001
versus AACGRKInh, Sham, and ShamGRKInh).
FIGURE 13. Down-regulation of endogenous Ucp1 retards the develop-
mentof cardiacdysfunction inapressureoverload-inducedheart failure
model.A andB, endogenousUcp1expression (A) andUcp1protein level (B) in
hearts of B6mice with 2months of AAC and transduction of a control lentivi-
rus (AACmiCont.) or a lentivirus targeting Ucp1 by RNAi (AACmiUcp1) rel-
ative to sham-operated B6 controls. C, down-regulation of Ucp1 retarded
the AAC-triggered decrease in the left ventricular ejection fraction
(AACmiUCP1) relative to AAC-subjected B6 mice transduced with a control
lentivirus (AACmiCont.). The data are shown as the means S.D. (n	 4; *,
p 0.05, and ***, p 0.001 versus Sham B6; Dunnett’s multiple comparison
test). IB, immunoblot.
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S273A transgenic hearts, the transgenic expression of PPARG
caused significantly less up-regulation of selectedPparg targets,
and only the expression of cardiac Adipoq and Fasn was signif-
icantly increased in 4-week-old mice (Fig. 14G). The up-regu-
lation of Adipoq in PPARG transgenic mice may have contrib-
uted to the cardiac hypertrophy (cf. Fig. 14, B and E) because
Adipoq is required for pro-hypertrophic signaling during pres-
sure overload (44).
In agreement with the heart failure-like phenotype of
PPARG-S273A-expressing mice, the cardiomyocyte energetics
of neonatal cardiomyocytes from PPARG-S273A transgenic
mice showed an overall depressed substrate metabolism under
basal conditions with predominant glycolysis. This heart fail-
ure-like substrate use was not rescued by co-expression of
GRKInh (Fig. 14H). Conversely, PPARG-expressing car-
diomyocytes showed predominant -oxidation under basal
conditions indicative of lipid load, which was retarded by
GRKInh (Fig. 14H). Upon induction of an adult-like metabo-
lism by the 3F protocol, PPARG-expressing cardiomyocytes
shifted to a heart failure-likemetabolic substrate use (Fig. 14H).
In contrast to PPARG-S273A, the development of the PPARG-
induced heart failure-like phenotype was retarded by GRKInh
(Fig. 14H). Together these findings provide evidence for an
enhanced cardiac deterioration of PPARG-S273A transgenic
mice compared with PPARG-WT mice. Moreover, GRKInh
was inefficient in retarding the development of the PPARG-
S273A-induced cardiometabolic dysfunction and the up-regu-
lation of PPARG-S273A-regulated targets.
Discussion
In this study, we investigatedwhetherGRK2 inhibition could
be a specific approach for targeting of the dysfunctional cardiac
substratemetabolism,which is characteristic of late-stage heart
failure (4–6). To reproduce the dysfunctional cardiac substrate
use, we generated a novel transgenic model with myocardium-
specific FASN expression. The model imitated the up-regula-
tion of FASN, which occurs in patients with heart failure (10,
11). In the context of cardiovascular disease and heart failure,
the up-regulation of FASN could be a direct consequence of
decreased cardiac output and insufficient oxygen supply
because FASN is a hypoxia-induced gene (39). Because cardiac
ischemia is triggered by major cardiovascular risk factors such
as pressure overload and atherosclerosis, up-regulation of
FASN could also be an early and causative event in the patho-
genesis of heart failure. In agreementwith this notion, we found
that the sole expression of FASN was sufficient to trigger the
signs of heart failure. Additionally, models of heart failure,
which imitated cardiovascular risk factors of patients such as
chronic pressure overload or advanced atherosclerosis, also
showed up-regulation of cardiac Fasn (11).
How could FASN advance the symptoms of heart failure?
Initially, up-regulation of FASNmight be considered to be ben-
eficial by supplying more energy substrate to the heart muscle.
FIGURE 14. Low efficacy of GRKInh in retarding the cardiac phenotype of
PPARG-S273A transgenicmice.A, transgenic vector used for thegeneration
of transgenic mice with myocardium-specific expression of PPARG (and
PPARG-S273A). B, cardiac sections from newborn transgenic mice that
expressed PPARG-S273A or wild-type PPARG relative to a non-transgenic B6
control. Histological sectionswere stainedwith hematoxylin-eosin (H&E), and
are representative of three mice/groups. C, detection of PPARG/Pparg in car-
diac tissue extracts of 4-week-oldmicewith transgenic PPARG-S273A (S273A)
expression or PPARG expression (as indicated) relative to non-transgenic B6
controls (n 	 4 hearts/group). The lower panel is a control immunoblot (IB)
detecting Gnb. D and E, cardiac expression of PPARG (D), and the heart
weight-to-body weight ratio (E) of 4-week-old transgenic mice with ex-
pression of PPARG-S273A (S273A), PPARG-S273AGRKInh, PPARG, and
PPARGGRKInh are shown relative to age-matched non-transgenic B6 mice
(S.D., n	 4; *, p 0.05; ***, p 0.001 versus B6 control, Dunnett’s multiple
comparison test). F, increased postnatal mortality of mice with myocardium-
specific expression of PPARG-273A and PPARG-S273GRKInh comparedwith
mice expressingPPARG andPPARGGRKInh, respectively.G, gene expression
analysis of heart failure-related Pparg targets in hearts from4-week-old trans-
genic mice that express PPARG-S273, PPARG-S273GRKInh, PPARG, and
PPARGGRKInh relative to non-transgenic B6hearts (S.D.,n	 4, *,p 0.05,
and ***, p 0.001 versus B6 control, Dunnett’s multiple comparison test). H,
cardiomyocyte energetics was determined with neonatal cardiomyocytes
isolated from transgenic mice with myocardium-specific expression of
PPARG-S273A (S273A), PPARG-S273AGRKInh, PPARG, PPARGGRKInh, and
non-transgenic B6mice. The etomoxir-blocked fraction of OCR, which repre-
sents fatty acid-oxidation (left panels), the 2-deoxyglucose-blocked fraction
of ECAR, which represents glycolysis (middle panels), and the ratio of glycoly-
sis/-oxidation (right panels) were determined under basal conditions (upper
panels) and after the creation of an adult-like lipogenic milieu by the 3F pro-
tocol for 10 days (lower panels). The data are shown as themeans S.D.; n	
3 biological replicates; *, p 0.05, **, p 0.01, and ***, p 0.001 versus B6;
Dunnett’s multiple comparison test.
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However, in the long term, the uncontrolled accumulation of
palmitate as themajor lipid synthesized by FASN could activate
the heart failure-promoting transcription factor Pparg, as has
been documented by up-regulation of the Pparg-dependent
lipid metabolic process in Tg-FASN hearts and various other
models of heart failure. Because Fasn is also a Pparg target, a
vicious cycle of FASN/Fasn-induced Fasn could be triggered,
which finally results in cardiotoxic lipid load, dysfunctional
substrate use, and mitochondrial uncoupling due to palmitate-
triggered activation of Ucp1 (Fig. 15). The accumulation of
palmitate further promotes pro-apoptotic signaling and inhib-
its the pro-survival ERK axis (16). As a result, there is an
enhanced expression of heart failure-associated Pparg targets
that are triggered by ERK inhibition (36, 40), such as Adipoq
(44, 51, 52), Retn (45, 53), and Ucp1. Ensuing cardiomyocyte
death and remodeling and impaired cardiac energy generation
due to mitochondrial uncoupling could further aggravate the
symptoms of heart failure (Fig. 15).
Whenwe applied the Tg-FASNmice as amodel of a dysfunc-
tional cardiac substrate metabolism and an additional pressure
overload-induced heart failure model, we found that GRK2
inhibition directly interfered with the cardiac lipid accumula-
tion and mediated a reduction in the cardiac Fasn protein.
These activities could be attributed (at least partially) to several
mechanisms as follows: (i) the inhibition of the endogenous
Fasn up-regulation, a hypoxia-induced Pparg target (39); (ii) an
interference with fatty acid synthesis by preventing Acaca up-
regulation, which is also a Pparg-regulated gene induced by
hypoxia (38); and (iii) the enhancement of the fatty acid metab-
olism by re-sensitization of Adipor1 and Prkaa-mediated sig-
naling (14). As a consequence, GRK2 inhibition retarded the
development of the dysfunctional cardiac substrate use charac-
teristic of late-stage heart failure (Fig. 15).
Cardioprotective GRK2 inhibition required an intact ERK
axis to preserve the cardiac energetics because RKIP as a dual-
specific GRK2 and ERK cascade inhibitor promoted dysfunc-
tion of cardiomyocyte energetics, cardiac lipid load, and signs of
heart failure. Concomitantly, inhibition of the ERK cascade by
human RKIP was accompanied by decreased ERK-dependent
phosphorylation of Pparg. A decreased ERK-dependent phos-
phorylation of Pparg on serine 273 and serine 112 is known to
enhance Pparg activity and/or increase Pparg target gene
induction (36, 40, 43). Similarly, heart failure-related Pparg tar-
gets are triggered by RKIP, resulting in development of cardiac
lipid load and cardiac dysfunction (12).
Conversely, GRK2 inhibition by GRKInh led to an increased
ERK activation and enhanced the ERK-mediated phosphoryla-
tion of Pparg on serine 273. ERK axis activation could be part of
the cardioprotective gene expression program initiated by
GRK2 inhibition (12, 13, 41). Concomitantly, the expression of
heart failure-promoting Pparg targets was blunted, and the
appearance of the dysfunctional cardiac substrate metabolism
was retarded. In agreement with a causal role of PPARG-S273
phosphorylation in GRKInh-mediated cardioprotection, the
phosphorylation-deficient PPARG-S273A mutant promoted
dysfunction of the cardiomyocyte substrate metabolism and
caused enhanced postnatal death, which was largely insensitive
toGRKInh. In contrast, the phenotype of wild-type PPARGwas
less severe and could be (at least partially) rescued by GRK2
inhibition. Together, these data indicate that the ERK axis may
specifically counteract the heart failure-promoting transcrip-
tion factor Pparg by preventing heart failure-related Pparg tar-
get gene induction (36, 54) and/or could confer protection
against palmitate-induced endoplasmic reticulum stress (55).
Several heart failure-related Pparg targets are inhibited by
ERK-dependent Pparg inactivation (36, 40) with GRKInh, such
asAdipoq (44, 51, 52) andRetn (45, 53). By generatingTg-UCP1
mice with myocardium-specific UCP1 expression, our study
identifiedUCP1 as a heart failure-related ERK-regulated Pparg
target (36, 47), which was also down-regulated upon GRK2
inhibition (Fig. 15). Consequently, GRK2 inhibition could
decrease excessive mitochondrial uncoupling as a key event
that contributes to inefficient cardiac ATP generation and lip-
id-induced cardiomyocyte death in heart failure (49, 50).
Although the studywas performedwith experimentalmouse
models, the data could also be relevant for the human disease
because FASN up-regulation is a characteristic feature of
patients with heart failure (10, 11). Because PPARG up-regula-
tion occurs in heart failure patients with pressure-overloaded
heart and metabolic syndrome (56), GRK2 inhibition is
expected to disrupt a vicious FASN/PPARG cycle in patients
who suffer frommultiple risk factors (Fig. 15). Such a situation
wasmodeledwith rosiglitazone-treatedApoE/mice because
thesemice are prone to the development of atherosclerosis and
insulin resistance (57), and thereby mimic the risk profile of
patients with enhanced PPARG activation and cardiovascular
disease. In this model, Pparg activation triggered the up-regu-
lation of Fasn and signs of heart failure within 2 months. The
causal interplay between Fasn and Pparg-induced cardiotoxic-
ity was demonstrated by RNAi-mediated inhibition of Fasn,
which prevented the Pparg-induced cardio-lipotoxicity and
signs of heart failure. Because GRK2 inhibition also mediated
the down-regulation of FASN-dependent cardio-lipotoxicity,
patients with highmorbidity andmultiple risk factorsmay ben-
efit from GRK2 inhibition. The additional insulin sensitivity-
enhancing activity of GRK2 inhibition (13, 58) may further
increase the value of such a strategy.
Moreover, heart-specific GRK2 inhibition could become a
cardioprotective combination partner for a novel class of insu-
lin sensitivity-enhancing PPARG activators, which rely on the
inhibition of ERK-dependent PPARG phosphorylation for
antidiabetic activity (36), but they have promoted signs of heart
failure in clinical trials (59).
FIGURE 15. Scheme illustrates cardioprotective effects of GRK2 inhibi-
tion, which target the cardiometabolic dysfunction of late-stage heart
failure. The histology image presents a cardiac section from an 8-month-old
ApoE/ mouse with signs of heart failure induced by 2 months of Pparg
activation with rosiglitazone.
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In sum, our study provides strong evidence that cardiopro-
tective GRK2 inhibition specifically targets the dysfunctional
cardiac substrate use that is a symptom of late-stage heart fail-
ure (Fig. 15). The identified targeting approach could stimulate
the development of new therapeutic strategies.
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